ARVN

Arvinas, Inc.

A biotech company pioneering a new kind of medicine that works like a cellular "molecular matchmaker": instead of blocking disease-causing proteins, its PROTAC drugs tag them for the cell's own garbage disposal (the proteasome) to shred and recycle. Founded in 2013 by Yale professor Craig Crews, Arvinas grew out of his earlier company Proteolix, and in 2026 its breast-cancer therapy vepdegestrant, developed with Pfizer, became the first FDA-approved PROTAC treatment. It focuses on cancer and neurological disease.